Moderna's mRNA Flu Vaccine Approved for Adults Over 50 by FDA

The FDA has approved Moderna's mFLUSIVA, an mRNA-based seasonal influenza vaccine, for adults aged 50 and older. This marks Moderna's first mRNA flu vaccine and its fourth FDA-approved product, expanding vaccination options for older adults and demonstrating the broader application of mRNA technology.